AOTMiT: The Transparency Council will evaluate drugs, incl. for prostate cancer, AD and non-small cell lung cancer

The agenda includes:
Preparation of positions on the legitimacy of changing medical technology in the field of:
• guaranteed services in the field of ICD-9 procedures: 84,502 - introduction of growth factors of autogenous origin and ICD-9: 84,503 - introduction of growth factors from stem cells with an indication of the scope of indications for use,
• PET/MRI health care services with the use of [18F] -FDG in oncological indications (for initial diagnostics and treatment control in children and adolescents, breast gland, liver, pelvic organs, i.e. ovaries, prostate, anus, as well as head and neck ),
• PET/MRI health care services with the use of [18F] -FDG or 18F-florbetapir, or 18F-flutemetamol, or 18F-florbetaben in neurological indications (for oncological diseases of the CNS, epilepsy, dementia),
• PET/MRI healthcare services with the use of [18F] -FDG in cardiological indications (for the assessment of myocardial viability, myocarditis, sarcoidosis, heart cancer).
Preparation of drug assessment positions:
• Xtandi (enzalutamidum) as part of the drug program: "Treatment of hormone-sensitive metastatic prostate cancer (ICD-10 C61)",
• Doptelet (avatrombopag) as part of the drug program: "Treatment of adult patients with ITP (ICD-10: D69.3)",
• Olumiant (baricitinibum) under the drug program: "Treatment of patients with severe and moderate atopic dermatitis (ICD-10: L20)",
• Tecentriq (atezolizumabum) as part of the drug program: "Treatment of non-small or small cell lung cancer (ICD-10 C34)".
Preparation of opinions on draft health policy programs of local government units:
• "Program for the prevention of depressive disorders for children and adolescents from primary schools" (Żary),
• "Program of health policy in the field of prevention of early detection of breast cancer among the inhabitants of the Poznań poviat".
Preparation of an opinion on the coverage of drugs containing active substances with reimbursement:
• donepezilum in the indications: dementia with Lewy bodies; Parkinson's dementia,
• rivastigminum in the indication: dementia with Lewy bodies,
• quetiapinum in the indication: psychiatric disorders other than those mentioned in the SmPC in patients with dementia.

Source: AOTMiT